Night-Time Apomorphine Infusion: Who Are the Best Candidates? - HAL Accéder directement au contenu
Article dans une revue Movement Disorders Clinical Practice Année : 2023

Night-Time Apomorphine Infusion: Who Are the Best Candidates?

Résumé

Background: We recently demonstrated in a randomized controlled trial (APOMORPHEE, NCT02940912) that night-time only subcutaneous apomorphine infusion improves sleep disturbances and insomnia in patients with advanced Parkinson's disease and moderate to severe insomnia. Objectives: To identify the best candidates for receiving night-time only subcutaneous apomorphine infusion in routine care. Methods: In this post-hoc analysis of APOMORPHEE, we compared the characteristics of patients according to whether they chose to continue night-time only subcutaneous apomorphine infusion at the end of the study period or not. Results: Half of the patients (22/42) chose to continue the treatment. Off duration (day or night), painful Off dystonia, and insomnia severity at baseline were associated with night-time only apomorphine continuation. Multivariate analysis retained only Off duration as an independent predictor of continuation. Conclusions:The best candidates for night-time only apomorphine are patients with severe and prolonged Off periods (day or night) and severe insomnia.
Fichier principal
Vignette du fichier
Cochen De Cock - Night‐Time Apomorphine Infusion Who Are the Best Candidates.pdf ( 194.06 Ko ) Télécharger
Origine : Publication financée par une institution
Loading...

Dates et versions

hal-04148898, version 1 (05-07-2023)

Licence

Paternité - CC BY 4.0

Identifiants

Citer

Valérie Cochen de Cock, Pauline Dodet, Smaranda Leu-Semenescu, Cécile Aerts, Beatriz Abril, et al.. Night-Time Apomorphine Infusion: Who Are the Best Candidates?. Movement Disorders Clinical Practice, 2023, 10 (8), pp.1192-1197. ⟨10.1002/mdc3.13799⟩. ⟨hal-04148898⟩
33 Consultations
54 Téléchargements
Dernière date de mise à jour le 26/06/2024
comment ces indicateurs sont-ils produits

Altmetric

Partager

Gmail Facebook Twitter LinkedIn Plus